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Abstract 
The diluted aerosols from a cigarette (3R4F) and an e-cigarette (Vype ePen) were compared in two commercially 
available in vitro exposure systems: the Borgwaldt RM20S and Vitrocell VC10. Dosimetry was assessed by measur-
ing deposited aerosol mass in the exposure chambers via quartz crystal microbalances, followed by quantification 
of deposited nicotine on their surface. The two exposure systems were shown to generate the same aerosols (pre-
dilution) within analytically quantified nicotine concentration levels (p = 0.105). The dosimetry methods employed 
enabled assessment of the diluted aerosol at the exposure interface. At a common dilution, the per puff e-cigarette 
aerosol deposited mass was greater than cigarette smoke. At four dilutions, the RM20S produced deposited mass 
ranging 0.1–0.5 µg/cm2/puff for cigarette and 0.1–0.9 µg/cm2/puff for e-cigarette; the VC10 ranged 0.4–2.1 µg/cm2/
puff for cigarette and 0.3–3.3 µg/cm2/puff for e-cigarette. In contrast nicotine delivery was much greater from the 
cigarette than from the e-cigarette at a common dilution, but consistent with the differing nicotine percentages in 
the respective aerosols. On the RM20S, nicotine ranged 2.5–16.8 ng/cm2/puff for the cigarette and 1.2–5.6 ng/cm2/
puff for the e-cigarette. On the VC10, nicotine concentration ranged 10.0–93.9 ng/cm2/puff for the cigarette and 
4.0–12.3 ng/cm2/puff for the e-cigarette. The deposited aerosol from a conventional cigarette and an e-cigarette 
in vitro are compositionally different; this emphasises the importance of understanding and characterising different 
product aerosols using dosimetry tools. This will enable easier extrapolation and comparison of pre-clinical data and 
consumer use studies, to help further explore the reduced risk potential of next generation nicotine products.
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Background
In the past decade the awareness and usage of electronic 
cigarettes (e-cigarettes) has increased exponentially, with 
over 2.6 million adults using the devices in the United 
Kingdom as surveyed in  2015 [6]. A study funded by 
Cancer Research UK further suggests there is now ‘near 
universal awareness of e-cigarettes’ [9]. Around 12% 
of Europeans have tried e-cigarettes at some point, and 
roughly 2% report continued use [13]. The use of elec-
tronic-cigarettes and other vapourising devices by those 
in the United States is also on the rise, with estimations 
from a recent survey suggesting that 2.6–10% of adults 
in the US now vape [35]. Public Health England recently 
reported that compared to cigarettes, electronic ciga-
rettes may be about 95% less harmful and could be a 
potential aid for smokers trying to quit [27].
The US Food and Drug Administration (FDA) pub-
lished a draft guidance indicating the scientific stud-
ies required to demonstrate significantly reduced harm 
and risk of nicotine and tobacco products, including the 
use of in  vitro assessment tools [15]. An in  vitro aero-
sol exposure system supports such an approach, where a 
machine system will generate, dilute and deliver aerosols 
from cigarettes or e-cigarettes (or other nicotine deliv-
ery devices) to cell cultures at the air–liquid interface 
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(ALI) in a chamber or a module, mimicking a physi-
ological aerosol exposure. There are many examples 
where in vitro tests have been used to assess the biologi-
cal impact of smoke from tobacco products [7, 8, 22, 23, 
25, 29, 31, 32, 40, 41]. But despite the apparent ubiquity 
of e-cigarettes, in  vitro testing has only recently been 
adopted, and with some equivocal results [10, 28, 30, 36, 
37, 42].
The in vitro aerosol exposure environment was estab-
lished to enable the testing of tobacco smoke and other 
aerosol products in a more physiologically relevant man-
ner—with whole smoke and whole aerosols delivered to 
in  vitro cultures at the ALI. There are various exposure 
systems available for such tests, many summarised in 
Thorne and Adamson [40]. However, most of these com-
mercially available systems were originally designed and 
intended for use with cigarettes only, well before e-cig-
arettes and other next generation nicotine and tobacco 
products became commonplace. These systems can eas-
ily be adapted to enable the assessment of e-cigarettes, 
tobacco heating products (THPs) or even medicinal 
nicotine inhalers; however careful characterisation of 
the generated aerosol is required (at the point of genera-
tion and at the point of exposure) to enable comparisons 
before conclusions can be made from the associated bio-
logical responses.
There are many and various exposure systems avail-
able for the assessment of inhalable products; they differ 
in size, cost, mechanics, and paired exposure chamber. A 
complete exposure system requires an aerosol generator, 
a dilution route and exposure chamber (also called mod-
ule, plate or exposure device in certain set-ups) in which 
the biological culture is housed. Some are commercially 
available and others are bespoke laboratory set-ups [40]. 
There are certain technical and experimental challenges 
using next generation nicotine and tobacco products on 
these traditional smoking machines. These include differ-
ences in puffing regimes, greater aerosol density/viscos-
ity, issues with condensation in transit and manual device 
activation, to name just a few. It is also notable that, 
although the overall conditions of an exposure system 
can be controlled in terms of smoke dilution and smok-
ing regimen, it is difficult to measure the actual deposi-
tion of smoke on culture inserts [25]. Furthermore, we 
should not assume that what is known about tobacco 
smoke aerosol generation, dilution and delivery in such 
exposure systems will apply to the aerosol of these new 
products, as their aerosols are not compositionally or 
chemically the same; exposure must be characterised 
[39]. Cigarette smoke aerosol has a visible minority par-
ticle fraction (5%) suspended within an invisible majority 
gas and vapour phase in air; this vapour phase compris-
ing principally products of combustion [21]. Looking at 
next generation nicotine and tobacco products, recent 
data suggest THP aerosol has a lower vapour phase mass 
because the tobacco is at sub-combustion temperatures 
usually <350 °C [38]. E-cigarette aerosol is generated with 
coil heater temperatures reported as ranging 40–180  °C 
[11] and is best described as a mist [5]. It is predomi-
nately homogeneous particles in air with very low levels 
of volatile species; in addition to its simpler composition, 
the e-cigarette aerosol contains substantially lower levels 
(88 to >99%) of regulatory interest toxicants as compared 
with tobacco cigarette smoke [26]. Thus quantification of 
what the cell cultures are exposed to at the interface (the 
dosimetry) is pivotal in supporting the biological testing 
of next generation nicotine and tobacco products with 
such different aerosols.
Dosimetry tools and methods can assess many aspects 
of the test article’s aerosol and provide important data to 
relate biological response following exposure to the actual 
dose of aerosol encountered by the cells (thus confirm 
aerosol delivery in biological assay systems showing par-
tial or no biological response to exposure). An example 
would be the direct mass measurement of total deposited 
particles at the exposure interface, using a quartz crystal 
microbalance (QCM) device [4]. As particles deposit on 
the crystal’s surface its mass loading, and thus its natural 
oscillation frequency, changes which can be converted to 
an increase in deposited mass. QCMs provide real-time 
data, are simple to use and are useful for quality assur-
ance purposes too, confirming within an exposure that 
the culture in the exposure chamber is indeed receiv-
ing the aerosol dilution that is being reported. Another 
example of a dosimetry method complementing QCMs is 
the quantification of a chemical marker within the sur-
face deposit (of a QCM or a cell culture insert) identify-
ing how much of a certain chemical/compound is being 
exposed to cells in culture. Nicotine is a good example 
as it is common amongst the inhalable products we wish 
to assess. Additionally, there are methods published and 
in ongoing development to assess components of the 
vapour phase, such as carbonyl quantification [19, 25] 
and time of flight mass spectrometry (TOF–MS) [34], 
as well as trace metal quantification in aerosol emissions 
[24]. With tools and approaches like these, dosimetry can 
allow different test products to be directly compared, be 
employed as a quality assurance tool during exposure and 
demonstrate physiologically relevant exposure.
The ultimate aim of this study was to compare smok-
ing machine exposure systems and products. Herein we 
look at two commercially available aerosol exposure sys-
tems, the Borgwaldt RM20S (Fig. 1) and the Vitrocell VC 
10 (Fig. 2; Table 1). The machines are similar in that they 
both have a rotary smoking carousel designed to hold 
and light cigarettes, puff, dilute smoke and deliver it to 
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an exposure chamber housing in vitro cultures. Thereaf-
ter they differ in mechanical set-up and dilution princi-
ples; the RM20S having 8 independent syringes to dilute 
aerosol (Fig. 1); the VC 10 having only one syringe which 
delivers the aliquot of smoke to an independent dilution 
bar where air is added and a subsample drawn into the 
exposure chamber via negative pressure (Fig.  2). Both 
systems are paired with different exposure chambers and 
these are detailed in Table  2. In overview we can con-
clude that the systems are largely dissimilar, but achieve 
the same outcome. Furthermore without dose alignment 
even the raw data (based on each machine’s dilution prin-
ciple) are not directly comparable.
We have investigated and assessed both exposure sys-
tems for deposited aerosol particle mass and nicotine 
measurements using a reference cigarette (3R4F, Uni-
versity of Kentucky, USA) and a commercially avail-
able e-cigarette (Vype ePen, Nicoventures Trading Ltd., 
UK). Repeatability of aerosol generation was assessed 
by quantifying puff-by-puff nicotine concentration at 
source by trapping aerosol on Cambridge filter pads 
(CFPs) [Figs. 1b, 2b, asterisked rectangles under position 
(i)]. CFPs are efficient at trapping nicotine which largely 
resides in the condensed particulate fraction of these 
aerosols; CFP efficiency for cigarette smoke is stated as 
retaining at least 99.9% of all particles (ISO 3308:2012), 
and for e-cigarette aerosols CFPs have been shown to 
have a nicotine capture efficiency greater than 98% [5]. 
Exposure interface dose was assessed in two ways: gravi-
metric mass of deposited particles with QCMs and quan-
tification of nicotine from the exposed QCM surface. In 
this way the relationship between deposited mass and 
nicotine concentration across a range of dilutions on two 
systems could be realised for both products. Finally, these 
data would allow us to further understand those expo-
sure systems by enabling comparisons between the two 
types of product aerosols (in terms of mass and nicotine 
concentration) and importantly, demonstrate delivery of 
e-cigarette aerosol to the exposure interface.
Methods
Test articles—reference cigarette and commercially 
available e‑cigarette
3R4F reference cigarettes (University of Kentucky, USA), 
0.73  mg ISO emission nicotine (as stated on the pack) 
and 1.97 mg measured HCI emission nicotine [12], were 
conditioned at least 48 h prior to smoking, at 22 ± 1 °C 
and 60 ± 3% relative humidity, according to International 
Organisation of Standardisation (ISO) 3402:1999 [18]. 
Commercially available Vype ePen e-cigarettes (Nicov-
entures Trading Ltd., UK) with 1.58 ml Blended Tobacco 
Flavour e-liquid cartridges containing 18  mg/ml nico-
tine were stored at room temperature in the dark prior 
to use. The basic features of the two test articles are show 
in Fig. 3.
Per experiment, one cigarette was smoked at the 
Health Canada Intense (HCI) smoking regime: 2 s 55 ml 
bell profile puff with filter vents blocked, every 30 s [16]. 
Per experiment, one Vype ePen was vaped (puffed) at 
the same puffing parameters as the cigarette but with 
a square wave profile instead of bell. The same puff-
ing regime was selected to allow the most appropriate 
Fig. 1 a The 8-syringe Borgwaldt RM20S with the BAT exposure chamber (base) installed with three quartz crystal microbalances (QCMs). b Cross 
section of the RM20S; an e-cigarette is shown but the cigarette was puffed in the same way after being lit (i). Aerosol was drawn into the syringe 
where serial dilutions were made with air (ii) before being delivered to the exposure chamber (iii) where it deposited on the QCM surface. The 
asterisked rectangle under position (i) indicates a Cambridge filter pad (CFP) 
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Fig. 2 a The Vitrocell VC 10 Smoking Robot and 6/4 CF Stainless mammalian exposure module installed with four quartz crystal microbalances 
(QCMs). b Cross section of the VC 10; an e-cigarette is shown here but the cigarette was puffed in the same way after being lit (i). Aerosol was drawn 
into the syringe (ii) and delivered to the dilution bar where diluting air was added (iii). Diluted aerosol was drawn into the module (iv) and deposited 
on the QCM via negative pressure (v). The asterisked rectangle under position (i) indicates a CFP
Table 1 Technical specifications and  comparison between  the in  vitro exposure systems used in  this study: Borgwaldt 
RM20 and Vitrocell VC 10 [40]
Borgwaldt RM20S smoking machine Vitrocell VC 10 smoking robot
Dimensions (L × D × H) 2.4 m × 0.8 m × 1.3 m 1.5 m × 0.8 m × 0.85 m
Footprint Floor standing (2 m2) Bench top (1.2 m2)
Dilution system Syringe based independent dilution system capable 
of 8 independent dilutions per exposure device
Continuous flow dilution bar capable of 4 independ-
ent dilutions per exposure device
Dilution range 1:2–1:4000 (aerosol:air, v/v) Diluting airflow 0–12 l/min and exposure module 
vacuum sample rate 5–200 ml/min
Exposure throughput Up to 8 chambers with 3, 6, 8 inserts/chamber Up to 4 modules with 3 or 4 inserts/module
Computer controller Integrated computer Requires PC
Smoking regime ISO, HCI, Massachusetts, bell and square (e-cig) puff 
profiles
ISO, HCI and bespoke (human) smoking profiles, bell 
and square (e-cig) puff profiles
Tubing transit length to exposure device ~290 cm ~90 cm
Time taken from puff to exposure ~15–24 s (depending on dilution) ~8 s
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comparison between products and puffs (volume, 
duration and interval); however the square wave puff-
ing profile is required for e-cigarette vaping to ensure 
a continuous flow rate for the duration of the puff [17]. 
With continuous puff flow, aerosol is being generated 
from the first moment the puff activates; by contrast, 
if the bell curve profile was employed for e-cigarette 
puffing, insufficient aerosol would be generated across 
the puff duration. The e-cigarette (Vype ePen) used in 
this study is actuated via one of two surface buttons on 
the device body, high voltage (4.0 V—two arrows point-
ing towards the mouthpiece) and low voltage (3.6 V—one 
arrow pointing away from the mouthpiece). High volt-
age 4.0  V (2.8  Ω, 5.7  W) was used in all experiments, 
Table 2 Technical specifications and comparison between the two in vitro exposure chambers used in this study: BAT’s 
exposure chamber and Vitrocell’s mammalian exposure module [40]
Ø = diameter
BAT exposure chamber Vitrocell 6/4 CF Stainless mammalian exposure module
Approximate dimensions 12 cm Ø × 9 cm H 10 cm × 16 cm × 13 cm (D × W × H)
Approximate weight 0.65 kg 4.5 kg
Material Transparent Perspex® Polished stainless steel, glass and aluminium
Capacity 3 × 24 mm ø culture inserts
6 × 12 mm ø culture inserts
8 × 6.5 mm ø culture inserts
3 × 30 mm ø Petri dishes
1 × 85 mm ø Petri dish
3 or 4 × 24 mm ø culture inserts
3 or 4 × 12 mm ø culture inserts
3 × 35 mm ø Petri dishes
Integrated dose tool 1–3 QCMs 1–4 QCMs
Aerosol delivery to ALI Sedimentation, Brownian motion Sedimentation, Brownian motion
Effective residence time 52 s 79 s
Fig. 3 The cigarette and e-cigarette: University of Kentucky reference cigarette 3R4F (0.73 mg pack ISO and 1.97 mg HCI emission nicotine) and 
e-cigarette (Vype ePen) containing 28 mg nicotine blended tobacco e-liquid (1.58 ml cartridge at 18 mg/ml)
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hand-activated 1 s prior to syringe plunging, with a met-
ronome timer used to alert to puffing interval.
Aerosol generation and exposure: Borgwaldt RM20S 
smoking machine
For exposure chamber dosimetry, machine smoking/vap-
ing was conducted on the 8-syringe Borgwaldt RM20S, 
serial number 0508432 (Borgwaldt KC GmbH, Hamburg, 
Germany) (Fig. 1; Table 1) at four low dilutions of 1:5, 1:10, 
1:20, 1:40 (aerosol:air, v:v) as previously described [4]. The 
study was designed to draw comparisons between systems 
thus dose selection (low dilutions) was based on maxim-
ising deposited particle mass and nicotine concentration 
in a short duration (10 puffs for all experiments). Each 
product was smoked/vaped in three independent replicate 
experiments (n  =  3/product). Diluted aerosol was deliv-
ered to the exposure chamber housing three quartz crys-
tal microbalances (QCMs) [2]. Aerosol transit length from 
source to exposure was approximately 290  cm. For col-
lection at source (described fully later), the whole aerosol 
from each product was trapped by in-line Cambridge filter 
pads (CFPs) pre-syringe thus no dilution was required.
Aerosol generation and exposure: Vitrocell VC 10 smoking 
robot
For exposure chamber dosimetry, machine smoking/
puffing was conducted on the Vitrocell VC 10 Smoking 
Robot, serial number VC 10/141209 (Vitrocell Systems, 
Waldkirch, Germany) (Fig. 2; Table 1) at four low diluting 
airflows 0.125, 0.25, 0.5 and 1 l/min, and at an exposure 
module sample rate of 5  ml/min/well negative pressure 
as previously described [3]. Airflows were selected based 
on maximising deposited particle mass and nicotine 
concentration in a short duration (10 puffs for at source 
measurements, 5 puffs per product for chamber deposi-
tion measurements); furthermore, the airflow range is 
consistent with other Vitrocell module studies [25]. Each 
product was smoked/vaped in three independent repli-
cate experiments (n  =  3/product). Diluted aerosol was 
delivered to the exposure module housing four QCMs 
[3]. Aerosol transit length from source to exposure was 
approximately 90 cm. For collection at source (described 
next) the whole aerosol from each product was trapped 
by in-line CFP pre-syringe thus no dilution was required 
or set.
Collection of aerosol at source: puff‑by‑puff
ISO conditioned 44 mm diameter Cambridge filter pads 
(CFPs) (Whatman, UK) were sealed one each into a clean 
holder and installed into the aerosol transit line as close 
to the point of generation as possible (Figs. 1b, 2b, aster-
isked rectangles). Between puffs the exposed CFP was 
removed and placed in a clean flask and stoppered; the 
in-line pad holder was reinstalled with a fresh unexposed 
CFP and sealed. Thus we collected emissions to quan-
tify nicotine on a per puff basis, for the duration of 10 
puffs from each product on both machines. Each prod-
uct was smoked/vaped in three independent replicate 
experiments on both machines (n = 3/product/machine). 
Quantification of nicotine from the stoppered flasks con-
taining CFPs is described later.
Measurement of deposited particulate mass
Quartz crystal microbalance (QCM) technology (Vit-
rocell Systems, Waldkirch, Germany) has already been 
described for both exposure systems (RM20S [2]; VC 10 
[3]). Clean QCMs (5  MHz AT cut quartz crystals held 
between two Au/Cr polished electrodes; 25  mm diam-
eter, 4.9 cm2 surface area, 3.8 cm2 exposed surface area) 
were installed in their chamber housing units and stabi-
lised (zero point drift stability) prior to exposure. After 
the last puff, QCMs were left up to an additional 10 min 
to reach plateau phase, where recorded mass ceased to 
increase further, as per previously published dosimetry 
protocols on both machines [2, 3]. The total mass post-
exposure, recorded as micrograms per square centimetre 
(µg/cm2) was divided by the total puff number to present 
dosimetry on a mean per-puff basis (µg/cm2/puff).
Quantification of nicotine
Nicotine quantification by ultra high performance liq-
uid chromatography triple quad mass spectrometry 
(UPLC-MS/MS) was based on published methods [20, 
33]. All standards, QCM and CFP samples were spiked 
with d4-nicotine at a final concentration of 10  ng/ml as 
internal standard. Exposed QCM crystals were removed 
from their housing units without touching the deposited 
surface, and placed in individual flasks. HPLC-methanol 
was added to each flask: 3  ml for RM20S samples and 
2  ml for VC 10 samples (method differences are dis-
cussed later). d4-nicotine internal standard was added 
to each flask (10  µl/ml sample) and shaken for at least 
30 min at 160 rpm to wash the surface deposit from the 
crystal. Thereafter 1  ml of extracts were condensed in 
an Eppendorf Concentrator 5301 (Eppendorf, UK) for 
80 min at 30 °C (higher temperatures degrade the stand-
ard). Extracts were resuspended in 1  ml of 5% acetoni-
trile in water and pipetted into GC vials at 1 ml. The total 
nicotine quantified on the QCM (ng) was multiplied by 
the methanol extraction volume, divided by the crystal’s 
exposed surface area of 3.8  cm2 (the exposed diameter 
reduces from 25 mm to 22 mm due to the 0.15 cm hous-
ing ‘lip’) and by puff number to present total nicotine per 
area per puff (ng/cm2/puff).
Due to higher predicted source nicotine concentra-
tion, exposed CFPs placed in individual stoppered flasks 
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were extracted in 20  ml HPLC-methanol. An additional 
200  µl d4-nicotine internal standard was added to each 
flask (10 µl/ml sample consistent with QCM samples) and 
shaken for at least 30 min at 160 rpm to wash the trapped 
material from the pad. Thereafter 500 µl of extracts were 
condensed in an Eppendorf Concentrator 5301 (Eppen-
dorf, UK) for 80 min at 30 °C. Extracts were resuspended in 
1 ml of 5% acetonitrile in water and pipetted into GC vials 
at 500 µl with an additional 500 µl 5% acetonitrile in water. 
The quantity of nicotine was determined using a Waters 
Acquity UPLC (Waters, Milford, MA) connected to an 
AB Sciex 4000 Qtrap MS/MS using Analyst software. An 
Acquity UPLC HSS C18 column (particle size 1.7 µm, col-
umn size 2.1 × 50 mm) was used and the column tempera-
ture was maintained at 40 °C. The standards and samples 
were resolved using a gradient mobile phase consisting 
of 5  mM ammonium acetate and acetonitrile; the flow 
rate was 0.5 ml/min. The accuracy was evaluated by com-
paring the sample peak heights to a calibration curve of 
known nicotine concentrations ranging from 1 to 1000 ng/
ml internal standard for the QCMs, and 10–10,000 ng/ml 
internal standard for the CFPs. The acceptance criteria for 
the accuracy of the calibration curve was 100 ± 20%, the 
LOD was determined from standard deviation values of 
the signal to noise ratio of the calibration curve greater 
than 3:1, and the LOQ greater than 10:1.
Graphics, analysis and statistics
All raw data and data tables were processed in Microsoft 
Excel. The boxplots for source nicotine and interval plots 
for deposited mass and nicotine (Figs. 4a, 5, 6) were pro-
duced in Minitab 17. The puff-by-puff source nicotine 
chart and regression for mass and nicotine (Figs.  4b, 7) 
were produced in Excel. Comparisons of mean source 
nicotine from products on different machines were con-
ducted in Minitab by ANOVA test, with the ‘product’ 
(experimental repeat) as a random effect and nested 
within ‘machine’; differences between puff numbers 
for the same product were compared with a General 
Linear Model, non-nested with ‘product’ as a random 
effect again. A p value <0.05 was considered significant. 
Irrespective of exposure (total puff number) or nicotine 
extraction volume, all total deposited mass and nicotine 
data were normalised to surface area per puff.
Results
We wanted to attain confidence in aerosol generation 
repeatability prior to assessment of exposure cham-
ber dosimetry; this was to ensure there were no dif-
ferences between the two smoking machines for 
aerosol generation to begin with. Mean nicotine con-
centration per puff was quantified at source (100% 
aerosol) by in-line trapping with a CFP (n  =  3/puff/
product/machine). Mean 3R4F cigarette smoke nico-
tine concentration was 0.171  ±  0.055  mg/puff on the 
RM20S and 0.193  ±  0.055  mg/puff on the VC 10. 
For the e-cigarette, mean nicotine concentration at 
source was 0.049  ±  0.006  mg/puff on the RM20S and 
0.053 ±  0.012 mg/puff on the VC 10 (3.5 and 3.6 times 
less than the cigarette respectively) (Fig. 4a; Table 3). The 
mean analytical value for 3R4F reference cigarette nico-
tine concentration per puff at the HCI regime was pub-
lished at 0.189  mg/puff (1.97  mg/cig at 10.4 puffs/cig) 
[12]. As demonstrated, our obtained source nicotine data 
per puff for the cigarette on both machines was at the 
expected analytical values previously obtained (Fig.  4a 
dotted line). For the e-cigarette, in-house measurements 
have recorded 0.032 mg nicotine per puff for the 55:3:30 
regime at low voltage, and 0.0552  mg nicotine per puff 
for the 80:3:30 regime at high voltage. As we can see here, 
the puffing parameters (specifically the puff duration and 
square profile instead of bell) and voltage settings play a 
significant role in aerosol nicotine delivery. Our e-ciga-
rette aerosols was generated at 55:2:30 high voltage, but 
our mean nicotine concentrations at source sit reasona-
bly between the two measured values at regimes/voltages 
above and below. There was no statistically significant 
difference in nicotine concentration between machines; 
p  =  0.105 (for the two products tested). In generating 
per puff data we observed the cigarette concentration of 
nicotine increase from puff 1 to puff 10 as expected; the 
tobacco rod itself also acts as a filter where tar and nico-
tine will deposit down the cigarette, enriching the distill-
able material in the distal rod for later puffs (p ≤ 0.01 for 
both machines). Yet in contrast and again as predicted, 
the e-cigarette nicotine concentration per puff was highly 
consistent in delivery from puff 1–10; p = 0.284 for ePen 
on the RM20S and p  =  0.530 for ePen on the VC 10 
(Fig. 4b).
Deposited particle mass was recorded with QCMs at a 
range of dilutions in the most concentrated range on the 
Borgwaldt RM20S [1:5–1:40 (aerosol:air, v:v)] and a dose 
response was observed for both products whereby depos-
ited mass decreased as aerosol dilution increased. For the 
cigarette, deposited particle mass ranged from 0.08 to 
0.51  µg/cm2/puff. For the e-cigarette deposited particle 
mass in the same range was higher at 0.10–0.85 µg/cm2/
puff [Fig. 5 (top); Table 4]. Those directly exposed quartz 
crystals were then analysed for nicotine and the same 
dose–response relationship was observed with dilution. 
For the cigarette, QCM deposited (quartz crystal eluted) 
nicotine concentrations ranged 2.47–16.76  ng/cm2/puff; 
for the e-cigarette QCM deposited nicotine concentra-
tions were in the range 1.23–5.61  ng/cm2/puff [Fig.  5 
(bottom); Table 4]. Deposited particle mass and nicotine 
concentration was assessed on the Vitrocell VC 10 in the 
Page 8 of 16Adamson et al. Chemistry Central Journal  (2016) 10:74 
Fig. 4 a Boxplot showing mean nicotine concentration per puff at source from two products on two machines (n = 30/product/machine). The 
dotted line represents the published cigarette mean analytical target value. There was no significant difference between the same products tested 
on both machines: p = 0.105. The e-cigarette (mean) delivers 3.5 and 3.6 times lower nicotine concentration versus the cigarette (mean) on the 
RM20S and VC 10 respectively. b Individual nicotine values showing the puff-by-puff profile from two products on two machines (n = 3); p ≤ 0.01 
for cigarette puffs 1–10 on both machines, p = 0.284 and p = 0.530 for ePen puffs 1–10 on the RM20S and VC 10 respectively
Page 9 of 16Adamson et al. Chemistry Central Journal  (2016) 10:74 
Fig. 5 Boxplot showing QCM determined aerosol particle deposition from a cigarette and an e-cigarette on the RM20S (top). Deposited nicotine 
concentration from the washed QCM for a cigarette and an e-cigarette on the RM20S (bottom). Mass and nicotine values are the mean of three 
QCMs per chamber and three replicate experiments per product and dilution. Asterisks denote single data point outliers, as determined by Minitab
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Fig. 6 Boxplot showing QCM determined aerosol particle deposition from a cigarette and an e-cigarette on the VC 10 (top). Deposited nicotine 
concentration from the washed QCM for a cigarette and an e-cigarette on the VC 10 (bottom). Mass and nicotine values are the mean of four 
QCMs per exposure module and three replicate experiments per product and dilution. Asterisks denote single data point outliers, as determined by 
Minitab
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same way, in the range of dilutions 0.125–1.000  l/min 
(with a 5 ml/min exposure module sample rate by nega-
tive pressure). All measured values were higher than the 
RM20S. A dose response was observed for both products 
whereby deposited mass decreased as aerosol dilution 
increased. For the cigarette on the VC 10, deposited par-
ticle mass ranged from 0.36 to 2.12 µg/cm2/puff. For the 
e-cigarette, deposited particle mass in the same dilution 
range was 0.34–3.34  µg/cm2/puff [Fig.  6 (top); Table  5]. 
As before, those directly exposed QCMs were then ana-
lysed for nicotine. For the cigarette, QCM deposited 
(quartz crystal eluted) nicotine concentrations ranged 
10.02–93.94  ng/cm2/puff; for the e-cigarette QCM 
deposited nicotine concentrations were in the range 
3.98–12.28 ng/cm2/puff [Fig. 6 (bottom); Table 5].
Ratio differences between the cigarette and the e-cig-
arette were calculated for mass and nicotine on both 
machines, to get an insight into the relationship between 
the two different nicotine delivery products and how 
their diluted aerosols behaved across both systems. 
Absolute values between the two exposure systems were 
clearly different but the relationship between prod-
ucts for deposited mass and nicotine was mostly similar 
and consistent across dilutions and between machines 
(Tables 4, 5, ratio values). The ratio difference in depos-
ited mass between cigarette and e-cigarette (3R4F/ePen) 
on the RM20S at the dilutions tested ranged 0.60–0.81. 
The ratio difference in deposited nicotine concentration 
between cigarette and e-cigarette on the RM20S at the 
dilutions tested was higher and ranged 2.58–3.60. On 
Fig. 7 Relationship between deposited mass and nicotine concentration. Data from both exposure systems were combined. Cigarette (solid 
squares RM20S and open circles VC 10) R2 = 0.928 (Y = 0.0203x + 0.1452); e-cigarette (solid triangles RM20S and crosses VC 10) R2 = 0.769 
(Y = 0.2482x − 0.0808)
Table 3 Cigarette and  e-cigarette nicotine concentration per  puff at  source (pre-dilution) on  both machines at  the 
55:2:30 regime; mean ± standard deviation (n = 30 puffs/product/machine)
a Eldridge et al. [12]
Analytical target (mg/puff) Borgwaldt RM20S (mg/puff) Vitrocell VC 10 (mg/puff)
3R4F cigarette 0.189a 0.171 ± 0.055 0.193 ± 0.055
ePen e-cigarette N/A for this regime 0.049 ± 0.006 0.053 ± 0.012
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the VC10, those deposited mass ratios (3R4F/ePen) were 
in the same range as the RM20S in the lower dilutions 
(0.125–0.250  l/min) at 0.63 and 0.68 respectively, but 
diverged from the RM20S in the higher dilutions (0.500–
1.000  l/min) at 0.92 and 1.07 respectively. The ratio dif-
ference in deposited nicotine concentration between 
cigarette and e-cigarette on the VC 10 ranged 7.65–10.03 
at the first three dilutions but decreased to 2.52 at 1  l/
min. These ratio comparisons show agreement at all dilu-
tions on the RM20S; the VC 10 shows parity but there are 
greater product differences at higher air flow rates and 
we have previously reported variances in dose delivery 
from flow rates around 0.5 l/min [1].
A final graphic representation of the linear relation-
ship between deposited mass and nicotine concentra-
tion in  vitro was produced when all data (from both 
machines) was plotted for the two products in a regres-
sion (Fig.  7). The higher the deposited mass delivered 
from the cigarette the higher the concentration of nico-
tine (R2  =  0.93); conversely, the e-cigarette delivered a 
much greater mass and a lower concentration of nicotine 
in the same dilution ranges tested (R2 = 0.77). The chart 
also confirms the difference in dose delivery between the 
machines, with the VC 10 (crosses and circles) demon-
strating a greater range of mass and nicotine delivery 
than the RM20S (solid markers), based on the low dilu-
tions chosen for this study (Fig. 7).
Discussion
As part of a weight of evidence approach, the in  vitro 
exposure of a biological system to inhalable aerosols is 
one way of generating data to assess the potential of novel 
nicotine and tobacco products to demonstrate reduced 
risk. Such products include e-cigarettes: from disposable 
single-piece cigarette-like products, to modular devices 
with interchangeable parts, all available in a wide range 
of e-liquid flavours, ratios of solvent (glycerol:propelyne 
glycol) and nicotine concentration; and tobacco heating 
product (THP) devices: in which tobacco can be heated 
up to (but not usually above) 350  °C releasing nicotine 
and tobacco flavour with a reduced toxicant profile in the 
aerosol.
In this study, we aimed to characterise the genera-
tion and delivery of a commercially available e-cigarette 
(Vype ePen) aerosol compared to reference 3R4F ciga-
rette smoke in two in vitro exposure systems: the Borg-
waldt RM20S Smoking Machine and the Vitrocell VC 10 
Smoking Robot (Figs.  1, 2). Having two different expo-
sure systems with different modes of operation allows 
us the benefit of a greater understanding of the aerosol 
Table 4 Mean deposited mass (µg/cm2/puff)  ±  standard deviation and  mean nicotine concentration (ng/cm2/
puff) ±  standard deviation from  the RM20S; three QCMs per  chamber and  three replicate experiments per  product 
and dilution
Ratios are between the cigarette and the e-cigarette at each dilution (3R4F/ePen)
Dilution (1:X) 1:5 1:10 1:20 1:40
Product 3R4F EPen 3R4F EPen 3R4F EPen 3R4F EPen
Mean mass 0.51 ± 0.09 0.85 ± 0.21 0.26 ± 0.05 0.37 ± 0.14 0.13 ± 0.03 0.18 ± 0.02 0.08 ± 0.01 0.10 ± 0.01
Mean mass ratio 0.60 0.70 0.74 0.81
Mean (nicotine) 16.76 ± 7.42 5.61 ± 2.78 10.17 ± 4.13 2.83 ± 1.03 4.14 ± 1.25 1.61 ± 0.44 2.47 ± 0.84 1.23 ± 0.77
Mean (nicotine) ratio 2.99 3.60 2.58 2.01
Table 5 Mean deposited mass (µg/cm2/puff)  ±  standard deviation and  mean nicotine concentration (ng/cm2/
puff) ± standard deviation from the VC 10; four QCMs per module and three replicate experiments per product and dilu-
tion
Ratios are between the cigarette and the e-cigarette at each dilution (3R4F/ePen)
Dilution (l/min) 0.125 0.250 0.500 1.000
Product 3R4F EPen 3R4F EPen 3R4F EPen 3R4F EPen
Mean mass 2.12 ± 0.34 3.34 ± 0.42 1.15 ± 0.08 1.69 ± 0.19 0.66 ± 0.12 0.72 ± 0.17 0.36 ± 0.04 0.34 ± 0.03
Mean mass ratio 0.63 0.68 0.92 1.07
Mean (nicotine) 93.94 ± 25.62 12.28 ± 2.83 46.25 ± 8.69 4.90 ± 1.13 23.07 ± 7.06 2.30 ± 0.92 10.02 ± 2.56 3.98 ± 1.46
Mean (nicotine) ratio 7.65 9.44 10.03 2.52
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exposure environment. Aerosol generation was assessed 
by trapping with Cambridge filter pads (CFPs) at source 
and quantification of puff-by-puff nicotine concentra-
tion by UPLC-MS/MS. Diluted aerosol deposition at 
the exposure interface was characterised in the expo-
sure chamber (RM20S) and exposure module (VC 10) by 
measuring deposited particle mass with QCMs and then 
quantifying the deposited nicotine concentration per puff 
from their exposed surfaces by UPLC-MS/MS.
Source nicotine generation per puff for both products 
were in the region of expected analytical values previ-
ously obtained (Table  3; Fig.  4a). This is a positive out-
come demonstrating that aerosol generation for in vitro 
exposure is comparable to that from analytical smoking 
machines; in addition our nicotine quantification method 
has been adapted for our purposes and again differs from 
analytical methods. It was noted that with the cigarette 
the concentration of nicotine increased per puff, as pre-
dicted, yet with the e-cigarette nicotine concentration 
per puff was largely consistent in delivery. There was no 
statistically significant difference in mean nicotine con-
centration between products on different machines, 
p = 0.105. Mean values were obtained from 10 puffs and 
as is known there are significant puff-to-puff differences 
as the tobacco rod shortens, hence larger standard devia-
tion and significant difference between successive puffs 1 
through 10, p ≤ 0.01 (Fig. 4b). The e-cigarette displayed 
high repeatability in the puffing profile, and low puff-to-
puff variability resulting in a tighter standard deviation 
and no significant difference between successive puffs 1 
through 10, p =  284 and 0.530 for the RM20S and VC 
10 respectively (Fig. 4b). In addition to statistical conclu-
sions, we can also see that the obtained mean value for 
the cigarette on both machines was in the region of pre-
viously reported analytical targets (Fig. 4a) [12].
At the exposure interface (in the exposure chamber) 
the QCM results show that the e-cigarette delivered 
higher deposited mass but lower nicotine at a given dilu-
tion, whereas the reference cigarette delivered lower 
mass and much higher concentrations of nicotine at 
the same dilution as the e-cigarette (Figs.  5, 6 and 7). 
This is to be expected when we reconsider the compo-
sitional and chemical differences between aerosols; it is 
consistent with the differing nicotine percentages in the 
respective products. Deposited mass and nicotine show 
a concentration dependent relationship with both prod-
ucts on both machines. For the cigarette, an R2 value 
of 0.93 was observed; this linear correlation between 
trapped nicotine and smoke concentration was also 
observed by Majeed et  al. [25], R2 =  0.96 (albeit using 
a different Vitrocell exposure module and set-up). For 
the e-cigarette, a lower R2 of 0.77 gives some doubts over 
linearity and might suggest there are evaporation effects 
at very high dilutions. This could be device and/or e-liq-
uid specific and needs further investigation. Assessing 
different product aerosols within different exposure sys-
tems highlights the importance of dosimetric characteri-
sation. These exposure systems were originally designed 
for use with combustible products in mind. For e-ciga-
rette aerosols, noteworthy differences to cigarette smoke 
in such systems include visibly wetter aerosols condens-
ing in transit tubing (possibly restricting aerosol flow 
and impeding syringe function) and some concerns with 
device button activation synchrony (either manually, or 
automated with a separate robot) with the syringe puff-
ing to ensure the entire puff is activated and delivered. 
It is important to be aware of issues such as consistency 
of device activation and puffing as it will affect dose. A 
lot of these observations will also change depending on 
e-cigarette device type/design, e-liquid composition, 
device battery power and activation voltage, coil resist-
ance, exposure system, transit tubing length and so on. 
Thus it is crucial to understand each unique set-up and 
test article prior to in  vitro biological exposure. With 
applied dosimetry, such differences between systems, 
test articles, cell types and exposure duration become 
less relevant when biological responses can be presented 
and aligned against a common dose metric. The differ-
ences we observed in delivery between the two exposure 
systems are likely due to their engineering and dilution 
mechanisms (Table 1) as we have shown that generation 
at source was consistent between systems for the same 
product. The VC 10 demonstrated greater values for 
deposited mass (and thus nicotine concentration) (Fig. 7) 
and also greater ratio differences between products com-
pared to the RM20S, however their transit lengths from 
generation to exposure differ too, with the VC 10 being 
shorter than the RM20S, at 90 and 290 cm respectively. 
In addition, not only flow rate, but also droplet diame-
ter, diffusion, and gravitational settling play a significant 
role in the process of aerosol deposition in the Vitrocell® 
exposure module [25]. Despite these system differences, 
there was an apparent dose range overlap where 1:5 and 
1:10 on the RM20S were approximate to 0.5 and 1.0 L/
min on the VC 10, respectively (Figs. 5, 6). These obser-
vations can assist when comparing varied biological 
response data from our two systems. This approach will 
become even more important when comparing reported 
data from an ever varied source of test articles, biologi-
cal endpoints and exposure systems: dosimetry tech-
niques will be able to unite data and systems with diverse 
modes of dilution.
There are numerous and important chemical markers 
present in cigarette and e-cigarette aerosol which can be 
used to characterise dosimetry. In the first instance, nico-
tine was chosen as an appropriate dosimetric marker: it 
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is a cross-product category chemical which is common 
between cigarettes, e-cigarettes, THPs, shisha tobacco, 
oral tobaccos, pipe and loose tobaccos, and medicinal 
nicotine inhalers. In addition nicotine quantification is 
reasonably simplistic compared to that of other more 
complex, trace or volatile chemical compounds such 
as those found in the vapour phase of tobacco smoke. 
Data in this study were presented on a ‘per puff’ basis, 
this being deemed the lowest common denominator for 
comparison across products which are consumed differ-
ently. In  vitro a cigarette is usually machine smoked to 
butt length for around 10 ±  2 puffs/stick (cigarette and 
smoking regime dependent) whereas a single e-cigarette 
(Vype ePen in this case) with full e-liquid cartridge can 
be vaped (puffed) at the same regime as the cigarette in 
excess of 200 puffs, depending on usage patterns [26]. We 
also know from behavioural observations and nicotine 
pharmacokinetic studies that people consume different 
nicotine delivery products in different ways. A regular 
combustible cigarette usually delivers a nicotine peak of 
18–20 ng/ml in blood plasma shortly after smoking; one 
early study of e-cigarette use by naive e-cigarette con-
sumers observed much lower peak plasma nicotine val-
ues of 1–3  ng/ml [43]. Another study suggested higher 
nicotine plasma levels up to 23  ng/ml could attained 
after using e-cigarettes, though taking much longer to 
peak versus a cigarette [14]. Thus we already start to see 
a diversity of results and responses within the e-cigarette 
category. Knowing that people interact with these prod-
ucts differently gives an added justification for normalis-
ing in vitro data to ‘per puff’.
There are a few considerations to this study which the 
authors acknowledge. To compare generation of aero-
sol at source between the two systems the experimental 
design was balanced: all products on both machines were 
puffed 10 times and pads containing the trapped nicotine 
were washed in 20 ml methanol and spiked with 200 µl 
d4-nicoitne. However, for the comparison of deposited 
mass and nicotine at the exposure interface (in the cham-
ber) all RM20S data on all product aerosols were gener-
ated at 10 puffs and QCMs washed in 3 ml methanol, and 
for the VC 10 data all product aerosols were generated at 
5 puffs and their QCMs washed in 2 ml methanol. This 
was due to the evolution and improvement of our meth-
ods during the duration of this study. The implication for 
the VC 10 e-cigarette data is minimal, as we demonstrate 
that delivery from the Vype ePen device is similar for all 
puffs at source (Fig. 4b). Five minute run times (instead 
of 10 min) probably had a greater implication on VC 10 
cigarette data, as mean puff number was divisible by 5 
puffs rather than 10, omitting the latter, higher delivery 
puffs (Fig. 4b); it could be predicted that mean absolute 
deposited mass from the cigarette in the VC 10 exposure 
module be even higher then described here at 5 puffs. 
However, it is noted that the tar:nicotine ratio for the 
3RF4 cigarette is consistent for the two systems (Fig. 7). 
We observed one anomaly in deposited nicotine from the 
ePen on the VC 10: delivery was substantially different at 
the highest dilution, delivering more nicotine at 1  l/min 
than at 0.5 L/min despite delivering lower mass (Fig. 6). 
At these two dilutions on the VC 10 we made repeat 
measurements on numerous occasions and generated the 
same values for nicotine each time. Because these runs 
were based on 5  min exposures, the delivery was quite 
low and therefore prone to overlap between the doses. In 
our future planned dose work we are repeating nicotine 
measurements at 1  l/min and will employ an approach 
for assessment of other next generation nicotine products 
with longer dose run times of up to 60 min normalised to 
puff. We predict in this case that the difference between 
the dilutions may be clearer and in a defined linear rela-
tionship. Additionally, anomalies that may be caused by 
product difference or operator variability will be ironed 
out by longer duration exposure, where multiple prod-
ucts are consumed per run. These are learnings that will 
be carried forward into future studies. Another general 
limitation for us here was the lack of e-cigarette analyti-
cal data at the regime we used in this study (55:2:30 high 
voltage). There are numerous regimes and voltage setting 
an electronic device can be puffed at, and we have already 
talked about how puff duration is more important than 
volume, and that how higher voltage activation results in 
greater aerosol delivery. Our e-cigarette regime (55:2:30) 
was selected to make better comparisons with the HCI 
cigarette regime. Indeed analytical chemistry data at 
matched regimes will help align in  vitro dose data; that 
said we have shown herein that our exposure systems can 
produce repeatable aerosol delivery from the Vype ePen 
under the conditions we selected (Fig. 4). A final note on 
recording deposited mass data with QCMs: in this study 
as with our previous dose determination studies [2, 3] we 
allowed a plateau phase post-exposure for all remaining 
aerosol in the chamber to deposit; this final value is taken 
when mass no longer increases and remains stable. We 
employ this approach to compare varied and new prod-
ucts and exposure systems. During in  vitro biological 
exposure the chamber may be removed from the system 
directly after the last puff rather than waiting to plateau, 
and in this instance the remaining aerosol in the chamber 
will not impact upon the cells. This could result in signifi-
cantly lower recorded dose values, and anecdotal obser-
vations on the RM20S have shown that between run-end 
and plateau phase the deposited mass value can be up 
to 2.5 fold greater (data not shown). Again this is not 
so much of an issue as long as each dose determination 
method or approach is clearly detailed when presenting 
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the paired biological data. These are all considerations for 
comparing products, systems and biological endpoints 
equally and fairly in future investigations.
With the exponential rise of e-cigarette usage [9, 27], the 
inevitable and rapid evolution of next generation nicotine 
and tobacco products and our requirement to assess their 
potential to reduce biological effects in  vitro, dosimetry 
science and applications become more pivotal. Under-
standing the dosimetry of a given exposure system and 
the characteristics of the test article aerosol will ensure a 
better understanding of and confidence in aerosol deliv-
ery and biological exposure. We should not assume that 
the products of the future and their new aerosols will 
behave the same in these systems as the products before 
them; it is likely there may be some differences. As for 
product comparisons, dose to the biological system can 
be matched by deposited particle mass and/or nicotine 
concentration (in the first instance). Matching for nicotine 
concentration will mean that the cell culture is exposed to 
a greater amount of aerosol from the e-cigarette, pushing 
the biological system even harder for a response to e-ciga-
rette aerosol comparable to cigarette smoke.
We see the value in dosimetry for all future studies 
where products will be tested and compared, with dose 
tools and methods having many applications. We believe 
these applications could be ranked as follows: first, prove 
exposure in every experiment (quality assurance) and 
demonstrate physiologically relevant exposure; then 
compare and align diverse exposure systems; compare 
test articles; and finally compare cell types and align bio-
logical response data from varied sources. The results 
reported herein clearly demonstrate that the aerosols 
generated from both products are not the same, and this 
makes testing them in  vitro challenging, but also inter-
esting and insightful. Indeed both product aerosols look 
the same, are physically similar and deliver nicotine to 
the consumer via inhalation, and both have been dem-
onstrated to deliver test aerosol and nicotine in vitro, but 
how these aerosols are composed and deposit in these 
exposure systems when diluted with air have been shown 
to vary. This study emphasises the importance of dosim-
etry, in understanding the products being tested and the 
systems they are being tested in. This will facilitate accu-
rate interpretations of biological response data and ena-
ble easier extrapolation and comparison of pre-clinical 
data and consumer use studies.
Conclusions
The results of our in vitro dosimetry study show that:
  • e-cigarette aerosol is delivered to and detected at the 
exposure interface
  • at a common dilution, e-cigarette (Vype ePen) aero-
sol deposited mass is greater than cigarette smoke 
(3R4F)
  • at a common dilution, e-cigarette (Vype ePen) aero-
sol deposited nicotine concentration is less than ciga-
rette smoke (3R4F) (consistent with emissions)
  • deposited mass and nicotine concentration decreases 
with increased dilution
  • irrespective of exposure system, the delivered mass/
nicotine relationship is similar for each product; 
there is no difference between machines (p = 0.105)
  • Data from this study help to bridge two dissimilar 
exposure systems for future products assessment
  • despite system differences, there is dose range parity 
where 1:5 and 1:10 on the RM20S are approximate to 
0.5 and 1.0 l/min on the VC 10, respectively
  • for the first time we have demonstrated puff-by-puff 
nicotine concentration generated at source from two 
in  vitro exposure systems, consistent with reported 
analytical values
  • for the first time we have demonstrated a technique 
to quantify nicotine on the deposited QCM surface, 
enhancing gravimetric dose
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